IFP Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-14
Closed -$729 3540
2023
Q1
$729 Sell
14
-405
-97% -$26.1K ﹤0.01% 3134
2022
Q4
$22K Sell
419
-3
-0.7% -$190 ﹤0.01% 2815
2022
Q3
$22K Buy
422
+17
+4% +$1.05K ﹤0.01% 3008
2022
Q2
$21K Hold
405
﹤0.01% 2802
2022
Q1
$21K Buy
+405
New +$24.7K ﹤0.01% 2802
2019
Q4
Sell
-405
Closed -$20K 3036
2019
Q3
$20K Buy
+405
New +$20.8K ﹤0.01% 1762
2019
Q1
$90K Sell
1,603
-431
-21% -$22.8K 0.01% 729
2018
Q4
$94K Sell
2,034
-225
-10% -$11.6K 0.01% 1232
2018
Q3
$134K Hold
2,259
0.01% 1306
2018
Q2
$124K Sell
2,259
-597
-21% -$30.4K 0.01% 1362
2018
Q1
$135K Hold
2,856
0.01% 1203
2017
Q4
$135K Buy
2,856
+155
+6% +$7.26K 0.01% 1212
2017
Q3
$135K Buy
2,701
+627
+30% +$29.7K 0.01% 1376
2017
Q2
$95K Buy
2,074
+205
+11% +$8.85K ﹤0.01% 1552
2017
Q1
$79K Buy
1,869
+101
+6% +$4.23K ﹤0.01% 1657
2016
Q4
$69K Sell
1,768
-48
-3% -$1.94K ﹤0.01% 1685
2016
Q3
$76K Buy
1,816
+201
+12% +$8.25K ﹤0.01% 1543
2016
Q2
$60K Buy
1,615
+12
+0.7% +$471 ﹤0.01% 1661
2016
Q1
$90K Sell
1,603
-967
-38% -$37.6K 0.01% 729
2015
Q4
$130K Buy
+2,570
New +$127K 0.01% 1028

Other funds holding PBE

IFP Advisors's PBE Position: Q2 2023 in Review

IFP Advisors sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2023, closing a stake of 14 shares — an estimated $729 sold.

IFP Advisors first reported a position in PBE in Q4 2015 and held it in 20 quarters. The position peaked at $135K in Q1 2018. 96 funds tracked by Wall St. Rank hold PBE as of Q2 2023.

  • IFP Advisors reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2023 after selling out during the quarter.
  • IFP Advisors sold 14 Invesco Biotechnology & Genome ETF shares in Q2 2023, an estimated $729.
  • IFP Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q4 2015 and held it in 20 quarters.
  • IFP Advisors's Invesco Biotechnology & Genome ETF position peaked at $135K in Q1 2018.
  • 96 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2023.

Based on IFP Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.